Interferons as Therapeutic Agents for Infectious Diseases

被引：27

作者：

Bergman, Scott J. ^{[1
,2
]}

Ferguson, McKenzie C. ^{[2
]}

Santanello, Cathy ^{[3
]}

机构：

[1] So Illinois Univ, Sch Med, Div Infect Dis, Edwardsville, IL 62026 USA

[2] So Illinois Univ Edwardsville, Dept Pharm Practice, Sch Pharm, Edwardsville, IL 62026 USA

[3] So Illinois Univ Edwardsville, Sch Pharm, Dept Pharmaceut Sci, Edwardsville, IL 62026 USA

来源：

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA | 2011年 / 25卷 / 04期

关键词：

Interferon-alpha; Viral hepatitis; Respiratory tract infection viruses; Common cold; Human papillomavirus; Genital warts; Vaccine; Adjuvant; HEPATITIS-C VIRUS; RECURRENT RESPIRATORY PAPILLOMATOSIS; HUMAN-PAPILLOMAVIRUS; ALBINTERFERON ALPHA-2B; RHINOVIRUS INFECTION; INTRANASAL INTERFERON-ALPHA-2B; ANTIVIRAL ACTIVITY; GENETIC-VARIATION; RANDOMIZED-TRIAL; I INTERFERON;

D O I：

10.1016/j.idc.2011.07.008

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

This article explains the rationale for development of interferons as therapeutic agents, and describes commercial products available today. It also provides a summary of studies that have been performed with interferons for use as exogenous biological response modifiers in viral infections. Overall, the best data exist for treatment of viral hepatitis B and C, for which interferons are a cornerstone of therapy. Although infections with human papillomavirus and common cold viruses sometimes respond favorably to interferons, their outcomes are far from ideal. Finally, the role of interferons as vaccine adjuvants is still being explored but could be promising.

引用

页码：819 / +

页数：17

共 102 条

[21] The Interferon Inducible Gene: Viperin [J].

Fitzgerald, Katherine A. .

JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2011, 31 (01) :131-135

[22]

FITZGIBBON JE, 1998, INT C ANT AG CHEM SA, V38, P367

[23] Biphasic Vesicles for Topical Delivery of Interferon Alpha in Human Volunteers and Treatment of Patients with Human Papillomavirus Infections [J].

Foldvari, Marianna ;

Badea, Ildiko ;

Kumar, Praveen ;

Wettig, Shawn ;

Batta, Ravinder ;

King, Martin J. ;

He, Zhihong ;

Yeboah, Emmanuel ;

Gaspar, Kimberly ;

Hull, Peter ;

Shear, Neil H. .

CURRENT DRUG DELIVERY, 2011, 8 (03) :307-319

[24] Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C [J].

Forestier, Nicole ;

Reesink, Hendrik W. ;

Weegink, Christine J. ;

McNair, Lindsay ;

Kieffer, Tara L. ;

Chu, Hui-May ;

Purdy, Susan ;

Jansen, Peter L. M. ;

Zeuzem, Stefan .

HEPATOLOGY, 2007, 46 (03) :640-648

[25] Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance [J].

Ge, Dongliang ;

Fellay, Jacques ;

Thompson, Alexander J. ;

Simon, Jason S. ;

Shianna, Kevin V. ;

Urban, Thomas J. ;

Heinzen, Erin L. ;

Qiu, Ping ;

Bertelsen, Arthur H. ;

Muir, Andrew J. ;

Sulkowski, Mark ;

McHutchison, John G. ;

Goldstein, David B. .

NATURE, 2009, 461 (7262) :399-401

[26] Use of interferon-alpha in recurrent respiratory papillomatosis: 20-year follow-up [J].

Gerein, V ;

Rastorguev, E ;

Gerein, J ;

Jecker, P ;

Pfister, H .

ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2005, 114 (06) :463-471

[27] Natural killer cells: Primary target for hepatitis C virus immune evasion strategies? [J].

Golden-Mason, L ;

Rosen, HR .

LIVER TRANSPLANTATION, 2006, 12 (03) :363-372

[28] RANDOMIZED COMPARATIVE TRIAL OF INTERFERON-ALPHA VERSUS PLACEBO IN HEPATITIS-B VACCINE NONRESPONDERS AND HYPORESPONDERS [J].

GOLDWATER, PN .

VACCINE, 1994, 12 (05) :410-414

[29]

Gubinelli E, 2003, J Dermatolog Treat, V14, P184, DOI 10.1080/09546630310009699

[30] Combined antiviral-antimediator treatment for the common cold [J].

Gwaltney, JM ;

Winther, B ;

Patrie, JT ;

Hendley, JO .

JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (02) :147-154

← 1 2 3 4 5 6 7 8 9 10 →